Paratek Pharmaceuticals — Novacea — Merger or Acquisition (September 2008)
32 slides from Paratek Pharmaceuticals's merger presentation, Sep 2, 2008
Slide 1: September 2008
September 2008 September 2008 Exhibit 99.3
Slide 2: Safe harbor statement
Safe harbor statement Safe harbor statement This slide deck contains forward-looking statements that are based upon current expectations within the meaning of the Private Securities Reform Act of 1995. We intend that such statements be protected by the safe harbor created thereby. Forward-looking st
Slide 3: Deriving new patient benefits from proven CNS drugs
Deriving new patient benefits from proven CNS drugs – Enhanced performance and new indications – Known safety and efficacy profile from established parent compounds – Reduced risk development strategy – Proprietary products; significant market opportunities : low-dose sublingual zolpidem, MOTN insom
Slide 4: Experienced management team
Experienced management team Experienced management team Idenix, Novartis Susan Koppy, VP Corp Dev Peninsula Pharmaceuticals Sharon Sakai, PhD, Sr Dir Regulatory Alza Nipun Davar, PhD, VP Pharm Sci Abbott, Lorex, Sanofi F. Steinberg, DO, consulting CMO Montreux Equity Partners Thomas P. Soloway, CFO
Slide 5: Intermezzo: low dose zolpidem for middle of the night insomnia
Intermezzo ® Low dose zolpidem for middle of the night (MOTN) insomnia Proposed indication statement: “ Intermezzo (zolpidem tartrate sublingual lozenge) is indicated for the treatment of insomnia characterized by difficulty returning to sleep after awakening in the middle of the night”
Slide 6: Rx insomnia therapeutics: a $4 billion market
10% to 15% seek physician help (3) $1.4B 2002 to $5B 2010 (2) New understanding of insomnia leads to new products to million people (2) Insomnia market growth (‘07 over ‘06): 9% in demand (TRx), 5% in value (1) Rx insomnia therapeutics: a $4 billion market Rx insomnia therapeutics: a $4 billion mark
Slide 7: Stanford Sleep Epidemiology Research Center: MOTN awakening, the #1 insomnia symptom
Stanford Sleep Epidemiology Research Center: MOTN awakening: the #1 insomnia symptom Stanford Sleep Epidemiology Research Center: MOTN awakening: the #1 insomnia symptom Large scale population based sleep epidemiology study, ~9,000 subjects over 6 years – Ohayon MM: Nocturnal Awakenings and comorbid
Slide 8: Phase 3 outpatient study: awakenings with at least 4 hours remaining in bed
8-9pm 9-10pm 10- 11pm 11- 12am 12-1am 1-2am 2-3am 3-4am 4-5am 5-6am 6-7am All MOTN treatment calls MOTN calls with >=4 hours remaining in bed Phase 3 outpatient study n = 294 : outpatient study: 96% of > 5,000 awakenings had at least 4 hrs remaining in bed : outpatient study: 96% of > 5,000 awakenin
Slide 9: MOTN awakenings typically occur not every night
MOTN awakenings typically occur to nights per week (1) , not every night, even in severe chronic insomnia 8 hour sleep aids require bedtime prophylactic dosing before an awakening occurs The ideal therapeutic would be used only when and if a patient needs help returning to sleep, not every night Hyp
Slide 10: Sleep lab clinical result: sleep onset with 3.5 mg dose
Sleep lab clinical result: 14 minute sleep onset with 3.5 mg dose Patients reported greater next day alertness vs. placebo Sublingual lozenge dissolves in ~ 2 minutes pH driven free base zolpidem 72% dose reduction vs. the most commonly prescribed brand Used only when needed (1) Ohayon MM: Nocturnal
Slide 11: Rapid bioavailability driven by Bimucoral technology
Hydrophilic zolpidem (88%) Hydrophilic zolpidem (50%) Lipophilic zolp (12%) Lipophilic zolpidem (50%) Lipophilic zolpidem (~ 100%) Normal Saliva pH = ~6 pH = 6.9 (“pKa”) pH = 9.5 pH = pKa pH < pKa pH > pKa Bimucoral technology drives pH above pKa Rapid bioavailability driven by Bimucoral technology
Slide 12: 3.5 mg delivered more zolpidem earlier than a ~3x higher Ambien dose
3.5 mg delivered more zolpidem earlier than a ~3x higher Ambien dose 3.5 mg delivered more zolpidem earlier than a ~3x higher Ambien dose PK comparison study: Intermezzo 3.5mg vs. Ambien 10mg PO n=36 Time (min) 9.3x 2.9x 1.4x 3.5 mg Ambien 10 mg Intermezzo 3.5mg Ambien 10mg p.o.
Slide 13: Intermezzo Phase 3 clinical results
Intermezzo ® Phase 3 clinical results Phase 3 clinical results Low dose zolpidem for middle of the night (MOTN) insomnia
Slide 14: Phase 3 sleep lab study (October 2006)
: Phase 3 sleep lab study (October 2006) : Phase 3 sleep lab study (October 2006) Principal investigators: Thomas Roth, PhD and Martin Scharf, PhD Study design: Double-blind, placebo-controlled study for objective (PSG) evaluation of sleep-onset safety and efficacy of 1.75 mg and 3.5 mg after MOTN a
Slide 15: Intermezzo achieved rapid sleep onset
44.6 17.0 30.7 14.2 23.7 37.3 : achieved rapid sleep onset, even in subjects with baseline awakenings >60 minutes : achieved rapid sleep onset, even in subjects with baseline awakenings >60 minutes p<0.003 vs. placebo p<0.001 vs. placebo p<0.001 vs. placebo p<0.001 vs. placebo Placebo 1.75mg 3.5mg P
Slide 16: Intermezzo put more patients back to sleep faster
: put more patients back to sleep faster vs baseline or placebo : put more patients back to sleep faster vs baseline or placebo 75% 56% 28% Phase 3 Sleep Lab Study n = 82
Slide 17: No reported hangover effects at 4 hrs vs placebo
61.88 61.59 60.57 62.36 64.25 63.56 : No reported hangover effects at 4 hrs vs placebo : No reported hangover effects at 4 hrs vs placebo Objective (DSST) Subjective (VAS) p<0.62 vs. placebo p<0.15 vs. placebo p<0.44 vs. placebo p<0.91 vs. placebo Placebo 1.75mg 3.5mg
Slide 18: Intermezzo helped patients feel better the next day
Placebo 1.75mg 3.5mg helped patients feel better the next day helped patients feel better the next day p<0.001 vs. placebo p<0.001 vs. placebo p<0.017 vs. placebo p<0.024 vs. placebo p<0.009 vs. placebo “Good” or “Excellent” next day ratings NS Phase 3 Sleep Lab Study n = 82 Sleep Quality Refreshing
Slide 19: Phase 3 outpatient study (January 2008)
Principal investigators: Andrew Krystal, MD and Thomas Roth, PhD Study design: Randomized, double-blind, placebo controlled, outpatient study to evaluate the safety and efficacy of 3.5 mg for the prn treatment of insomnia after MOTN awakening Study population: 294 non-elderly primary insomnia patien
Slide 20: Primary sleep onset endpoint confirmed in second Phase 3 study
69.42 56.37 68.13 38.22 : primary sleep onset endpoint confirmed in second Phase 3 study : primary sleep onset endpoint confirmed in second Phase 3 study p<0.0001 vs. placebo Latency to Sleep Onset (LSO MOTN ) week average Phase 3 outpatient study n = 294 week treatment Baseline week treatment Basel
Slide 21: Intermezzo achieved consistently faster sleep onset
: achieved consistently faster sleep onset vs. placebo over the entire 4 week treatment period : achieved consistently faster sleep onset vs. placebo over the entire 4 week treatment period Latency to Sleep Onset (LSO MOTN ) weekly Phase 3 outpatient study n = 294 Placebo 3.5mg p<0.0001 vs. placebo
Slide 22: Intermezzo produced ~30 minute improvement in sleep onset
: produced ~30 minute improvement in sleep onset vs. baseline : produced ~30 minute improvement in sleep onset vs. baseline Latency to Sleep Onset (LSO MOTN ) improvement over baseline Phase 3 outpatient study n = 294 Placebo 3.5mg
Slide 23: Patients reported next day effects better than placebo
4.71 5.24 4.87 5.59 : reported next day effects better than placebo : reported next day effects better than placebo p<0.0041 vs. placebo Next day alertness 4 week average Phase 3 outpatient study n = 294 MORE ALERT MORE SLEEPY 4 week treatment Baseline 4 week treatment Baseline Placebo 3.5mg Baselin
Slide 24: Average weekly treatment exposure
Average weekly treatment exposure Phase 3 outpatient study n = 294 : no evidence of increased medication use during four week study : no evidence of increased medication use during four week study
Slide 25: Intermezzo development timeline
development timeline development timeline Ph 3: sleep lab FDA meeting Bridging PK Elderly PK Ph 3: outpatient 3.5 mg Fed/Fast Mfr. 300kg batch Swallowed PK/PD Pre NDA meeting Projected NDA submission Projected launch Complete Projected Q4 2008 H1 2010
Slide 26: Intermezzo: Maximizing market potential
Intermezzo ® : Maximizing market potential : Maximizing market potential
Slide 27: Intermezzo commercialization strategy
: commercialization strategy : commercialization strategy anticipated to be the first prn insomnia therapeutic specifically for treatment of middle of the night awakenings Key marketing factors – Insomnia direct to consumer advertising spending in decline: • Q1 08: Lunesta -42%, AmbienCR -33%, Rozer
Slide 28: Intermezzo: Intellectual property
Intermezzo ® : Intellectual property : Intellectual property
Slide 29: Formulation and method of use patents pending
: formulation and method of use patents pending in US and international markets : formulation and method of use patents pending in US and international markets Formulation for transmucosal absorption: – priority date of February 17, 2004 – low dose zolpidem (about 1mg to about 5 mg) – formulated wit
Slide 30: Pipeline development
Pipeline development Pipeline development
Slide 31: Psychiatry pipeline product candidates
TO-2060: – Fixed combination product: olanzapine / ondansetron – Successful proof of concept study in alcohol abusing patients – Active IND: April 2008 – Seeking NIAAA and/or corporate partner funding TO-2061: – Fixed combination product: risperidone / ondansetron – Obsessive compulsive disorder pil
Slide 32: Registered trademark notice
is a registered trademark of Transcept Pharmaceuticals, Inc.